To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy

NCT03533959 · clinicaltrials.gov ↗

UNKNOWN

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease Progression

Interventions

DRUG: Alirocumab

Sponsor

Kobe University